Anthony M Reginato, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 375 Wampanoag Trail, Suite 202b, E. Providence, RI 02915 Phone: 401-649-4040 Fax: 401-649-4041 |
Edward V Lally, MD Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 375 Wampanoag Trail, Suite 202b, E. Providence, RI 02915 Phone: 401-649-4040 Fax: 401-649-4041 |
Stuart T Schwartz, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 375 Wampanoag Trail, Suite 202b, E. Providence, RI 02915 Phone: 401-649-4040 Fax: 401-649-4041 |
News Archive
Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.
The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).
Scientists from King's College London have announced that 16 human embryonic stem (hES) cell lines have been approved by the US National Institutes of Health (NIH) and placed on their Stem Cell Registry, making them freely available for federally-funded research in the USA.
"A study conducted in Uganda and Zambia by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) found high rates of syphilis and HIV co-infection among pregnant women in both countries," but showed that "integrating rapid syphilis screening and HIV testing for pregnant women was feasible, cost-effective, and helped to prevent transmission of syphilis and HIV from mother-to-child," PlusNews reports.
Advances in the treatment of children and adolescents with cancer have led to substantial improvements in survival, with a 5-year survival rate of childhood cancer close to 80%.
› Verified 7 days ago